Drug intelligence / Profile preview

TQD3606

Development stage: Phase 1
Lead developer: Chia Tai-Tianqing Pharmaceutical Group
Modality: Small Molecules
Administration: Intravenous

Overview

**TQD3606** is an investigational intravenous fixed-dose antibacterial combination of **meropenem** and **avibactam** being developed by Chia Tai Tianqing Pharmaceutical Group. Meropenem is a broad-spectrum carbapenem that inhibits bacterial penicillin-binding proteins and cell-wall synthesis, while avibactam is a reversible covalent inhibitor of susceptible serine beta-lactamases that protects meropenem from enzymatic degradation. The combination is in Phase 1 clinical development in China, including pharmacokinetic, safety, urinary-excretion, and renal-impairment studies for bacterial infections, including carbapenem-resistant bacterial infections.

Other names: meropenem + avibactamTQD-3606TQD3606TQD 3606

Targets

NeuraminidasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on TQD3606.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TQD3606.

Explore the full profile